FINWIRES · TerminalLIVE
FINWIRES

Canaccord Genuity Downgrades Apogee Therapeutics to Hold From Buy, Adjusts Price Target to $135.11 From $130

By

Apogee Therapeutics (APGE) has an average rating of buy and mean price target of $119.50, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles